BIO International 2023

Trailblazing biotech innovators require experienced, agile partners who understand that every day on your development path matters – partners who make it possible for you to maintain focus on the needs of today while preparing for the potential of tomorrow.

Syneos Health will be joining thousands of biotechnology and pharma leaders at the BIO International Convention—the industry’s largest partnering conference representing the full biotech ecosystem from across the globe.

Meet With Us

Our team of experts will be on the floor—and on the stage—at BIO 2023 to discuss how we can help you plan at any point along your product development journey.

Find us in the Business Forum or schedule a meeting to discuss your pressing challenges.

Book a Meeting

FEATURED SESSIONS:

Y Not: Are There Leadership Advantages Women Bring to the Biopharma C-Suite?

Monday, June 5 | 1-2pm EDT

Cynthia Isaac

Moderator: Cynthia Isaac, Managing Director, Syneos Health

In the words of Eleanor Roosevelt, “A woman is like a teabag—you can’t tell how strong she is until you put her in hot water.”Women leaders are answering the biopharma industry’s call for C-Suite leadership in record numbers – only to face glass cliffs instead of broken glass ceilings. Hear from leading female biopharma CEOs about why women are uniquely qualified to lead industry through the bear market with high-risk decision making, emotionally intelligent leadership, resilience, and collaboration. Join this candid discussion about why women leaders possess the attributes needed to boost stock price, build investor confidence, eliminate toxic cultures, and create inclusive workforces of the future.

Bringing Value Assessments into the 21st Century: A Multi-stakeholder Perspective

Wednesday, June 7 | 11am-12pm EDT

Aneeb Sharif

Moderator: Aneeb Sharif, Associate Director, Biosector 2 UK, Syneos Health

With growing inflation and economic turmoil, budgets are tighter than ever. Governments and other payers are looking to cut overall spending and one of their targets is again healthcare – specifically pharmaceuticals. To determine the value of medicines, and if/how spending can be reduced, governments and other payers are increasingly leaning on value assessments made by Health Technology Assessment Organizations (HTAs). Hear from a leading pharmaceutical company, one of America’s largest group purchasing organizations, an organization focused on value assessments, and a patient advocate, about how they recommend approaching value assessments to work better for patients or societies.

Women at the Crossroads in Gene Editing

Thursday, June 8 | 1-2pm EDT

Cynthia Isaac

Moderator: Cynthia Isaac, Managing Director, Syneos Health

In 2020, more than 71% of those with PhDs in health and medical sciences were women, strategically positioning female leaders in science to ride the wave of the gene editing revolution. The first CRISPR-based therapeutics and cell-line technology are ushering in the first generation of commercial gene-editing treatments, functionally curing patients with chronic complex diseases like sickle cell and potentially type 1 diabetes. Behind the movement sparked by female Nobel Laureates, it is the female scientists and executives who are leading the charge in the commercial development, regulation and pricing for therapies to revolutionize the way we treat diseases.

Additional Resources

詳細に興味がおありですか？Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:

Capabilities